Royalty Pharma plc
Royalty Pharma plc (RPRX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RPRX · as of Mar 31, 2025
Ownership Breakdown
467
Institutional Holders
▲ 43 vs Q4
$10.03B
Total Inst. Value
▲ $1.84B vs Q4
430.12M
Shares Outstanding
freeFloat 95.40%
322.17M
13F Shares Held
▲ 1.15M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RPRX largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
MORGAN STANLEY pharmaceutical preparations | 41.03M | 9.47% | 9.47% | $1.28T | May 15, 2025 | ▲ 1.50M |
FMR LLC pharmaceutical preparations | 39.40M | 9.09% | 9.09% | $1.23T | May 12, 2025 | ▲ 13.02M |
VANGUARD GROUP INC pharmaceutical preparations | 36.68M | 8.46% | 8.46% | $1.14T | May 9, 2025 | ▼ 676.6K |
BLACKROCK, INC. pharmaceutical preparations | 24.56M | 5.67% | 5.67% | $764.42B | May 2, 2025 | ▼ 890.7K |
BAILLIE GIFFORD & CO pharmaceutical preparations | 13.40M | 3.09% | 3.09% | $417.21B | May 7, 2025 | ▼ 732.2K |
SWEDBANK AB pharmaceutical preparations | 12.16M | 2.80% | 2.80% | $378.46B | Apr 14, 2025 | ▼ 6.7K |
VIKING GLOBAL INVESTORS LP pharmaceutical preparations | 10.56M | 2.44% | 2.44% | $328.86B | May 15, 2025 | ▼ 1.64M |
STATE STREET CORP pharmaceutical preparations | 9.52M | 2.20% | 2.20% | $296.24B | May 15, 2025 | ▼ 244.0K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 8.00M | 1.85% | 1.85% | $253.46B | May 13, 2025 | ▲ 686.9K |
ADAGE CAPITAL PARTNERS GP, L.L.C. pharmaceutical preparations | 6.25M | 1.44% | 1.44% | $194.56B | May 15, 2025 | ▼ 10.72M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
21
Increased
+25.48M shares1
New Positions
first time holders25
Decreased
−24.12M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.36M
+25.48M / −24.12M
Net new holders
-3
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RPRX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
8
Sell transactions
0.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Coyne Terrance P. EVP & CFO | May 26, 2026 | Sale | 64,399 | $53.98 | $3.48M | 0 | Form 4 ↗ |
Urist Marshall EVP, Research & Investments | May 20, 2026 | Sale | 13,684 | $52.75 | $721.8K | 18.2K | Form 4 ↗ |
Urist Marshall EVP, Research & Investments | May 14, 2026 | Sale | 13,684 | $53.06 | $726.1K | 31.9K | Form 4 ↗ |
Norden Gregory director | May 14, 2026 | Sale | 3,045 | $53.00 | $161.4K | 191.8K | Form 4 ↗ |
Legorreta Pablo G. CEO, Chairman of the Board | May 6, 2026 | Award | 143,821 | — | — | 1.24M | Form 4 ↗ |
Coyne Terrance P. EVP & CFO | May 6, 2026 | Award | 24,263 | — | — | 64.4K | Form 4 ↗ |
Hite Christopher EVP & Vice Chairman | May 6, 2026 | Award | 24,263 | — | — | 709.4K | Form 4 ↗ |
Urist Marshall EVP, Research & Investments | May 6, 2026 | Award | 18,197 | — | — | 45.6K | Form 4 ↗ |
Coyne Terrance P. EVP & CFO | Apr 28, 2026 | Sale | 1,875 | $49.78 | $93.3K | 40.1K | Form 4 ↗ |
Coyne Terrance P. EVP & CFO | Apr 28, 2026 | Sale | 32,916 | $49.78 | $1.64M | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Royalty Pharma plc (RPRX) is primarily owned by institutional investors, who hold approximately 74.9% of total shares outstanding. Company insiders own approximately 4.60%, while retail and public investors account for the remaining 20.50%.
The largest institutional shareholder of Royalty Pharma plc is MORGAN STANLEY, holding approximately 41.03 million shares — equal to 9.47% of outstanding shares — as of March 31, 2025.
A total of 467 institutional investors currently hold RPRX stock, with a combined institutional value of approximately $10.03 billion as of the most recent 13F filing period.
Frequently asked questions
RPRX ownershipRoyalty Pharma plc (RPRX) is primarily owned by institutional investors, who hold approximately 74.9% of shares. The largest shareholder is MORGAN STANLEY with a 9.47% stake. Company insiders hold 4.60%. Data sourced from SEC Form 13F as of March 31, 2025.